惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

N
Netflix TechBlog - Medium
罗磊的独立博客
云风的 BLOG
云风的 BLOG
Last Week in AI
Last Week in AI
Y
Y Combinator Blog
小众软件
小众软件
Blog — PlanetScale
Blog — PlanetScale
T
The Blog of Author Tim Ferriss
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
月光博客
月光博客
博客园 - Franky
F
Fortinet All Blogs
D
Docker
博客园 - 司徒正美
腾讯CDC
Recent Announcements
Recent Announcements
The Cloudflare Blog
B
Blog RSS Feed
GbyAI
GbyAI
T
Tailwind CSS Blog
雷峰网
雷峰网
Cyber Security Advisories - MS-ISAC
Cyber Security Advisories - MS-ISAC
博客园 - 三生石上(FineUI控件)
阮一峰的网络日志
阮一峰的网络日志

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings...
2026-05-01 · via All Articles on Seeking Alpha

Q1: 2026-04-30 Earnings Summary

EPS of -$0.30 misses by $0.16

 | 

Revenue of

$164.90M

(4.89% Y/Y)

misses by $21.71M

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call April 30, 2026 5:00 PM EDT

Company Participants

Atabak Mokari - CFO & Treasurer
Sean Maduck - President of Endocrinology
Roberto Vieira - President of Oncology
Joseph K. Belanoff - Co-Founder, President, CEO & Director
William Guyer - Chief Development Officer

Conference Call Participants

David Amsellem - Piper Sandler & Co., Research Division
Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division

Presentation

Operator

Thank you for standing by, and welcome to Corcept Therapeutics First Quarter 2026 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Atabak Mokari, CFO. Please go ahead.

Atabak Mokari
CFO & Treasurer

Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the first quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website.

Statements during this call other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements expressed or implied. The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available at the SEC's website. Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements.

Our revenue in the first quarter of 2026 was $164.9 million compared to $157.2 million in the prior year period. We have increased our 2026 revenue guidance to $950 million to $1.05 billion. Net